<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. ______)*
InKine Pharmaceuticals Company, Inc.
-------------------------------------------------------------
(Name of Issuer)
Common Stock
-------------------------------------------
(Title of Class of Securities)
457214104
-----------------------------------
(CUSIP Number)
Check the following box if a fee is being paid with this statement [_]. (A fee
is not required only if the filing person: (1) has a previous statement on file
reporting beneficial ownership of more than five percent of the class of
securities described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less of such class.)
(See Rule 13d-7).
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
Page 1 of 4 Pages
<PAGE>
------------------------------------------------------------------------------
NAME OF REPORTING PERSON
1. S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
Veron International Limited ("Veron")
N.A.
------------------------------------------------------------------------------
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
2. (a) [_]
(b) [_]
------------------------------------------------------------------------------
SEC USE ONLY
3.
------------------------------------------------------------------------------
CITIZENSHIP OR PLACE OF ORGANIZATION
4.
British Virgin Islands
------------------------------------------------------------------------------
SOLE VOTING POWER
5.
NUMBER OF 872,000 shares
SHARES -----------------------------------------------------------
SHARED VOTING POWER
BENEFICIALLY 6.
0
OWNED BY
-----------------------------------------------------------
EACH SOLE DISPOSITIVE POWER
7.
REPORTING 872,000 shares
PERSON -----------------------------------------------------------
SHARED DISPOSITIVE POWER
WITH 8.
0
------------------------------------------------------------------------------
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
9.
872,000 shares
------------------------------------------------------------------------------
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
10.
------------------------------------------------------------------------------
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
11.
3.77%
------------------------------------------------------------------------------
TYPE OF REPORTING PERSON*
12.
CO
------------------------------------------------------------------------------
Page 2 of 4 pages
<PAGE>
Veron International Limited (the "Reporting Person") hereby makes the following
statement on Schedule 13G with respect to certain shares of common stock of
InKine Pharmaceutical Company, Inc. (the "Issuer"):
Item 1.
(a) Name of Issuer;
InKine Pharmaceutical Company,Inc.
(b) Address of Issuer's Principal Executive Offices
Sentry Park East
1720 Walton Road, Suite 200
Blue Bell, PA 19422
Item 2.
(a) Name of Person(s) Filing:
Veron International Limited
(b) Address of Principal Business Office or, if none, Residence:
Top Floor, Chinachem Golden Plaza
77 Mody Road
Tsimshatsui East
Kowloon, Hong Kong
(c) Citizenship:
British Virgin Islands
(d) Title of Class of Securities:
This statement relates to shares of common stock, par value $0.0001
per share (the "Common Stock"), of the Issuer.
(e) CUSIP Number:
457214104
Item 3. If this statement is filed pursuant to Rule 13d-1(b) or 13d-2(b), check
whether the person filing is a:
N.A.
Item 4. Ownership
(a) Amount Beneficially Owned:
872,000 shares
(b) Percent of Class:
3.77%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote:
872,000 shares
(ii) shared power to vote or to direct the vote
0
Page 3 of 4 pages
<PAGE>
(iii) sole power to dispose or to direct the disposition of
872,000 shares
(iv) shared power to dispose or to direct the disposition of
0
In January 2000, the Reporting Person sold 628,000 shares out of its total
holding of 1,500,000 shares of Common Stock. No other transactions have
occurred since January 2000.
Item 5. Ownership of Five Percent or Less of a Class
If this statement is being filed to report the fact that as of the date
hereof the reporting person has ceased to be the beneficial owner of more than
five percent of the class of securities, check the following [X].
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
N.A.
Item 7. Identification and Classification of the Subsidiary Which Acquired the
Security Being Reported on By the Parent Holding Company
N.A.
Item 8. Identification and Classification of Members of the Group
N.A.
Item 9. Notice of Dissolution of Group
N.A.
Item 10. Certification
By signing below I certify that, to the best of my knowledge and belief,
the securities referred to above were acquired in the ordinary course of
business and were not acquired for the purpose of and do not have the effect of
changing or influencing the control of the issuer of such securities and were
not acquired in connection with or as a participant in any transaction having
such purposes or effect.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
August 15, 2000
---------------
Date
Veron International Limited
/s/ Joseph W.K. Leung
---------------------
Joseph W. K. Leung, Director
Page 4 of 4 pages
ATTENTION: INTENTIONAL MISSTATEMENTS OR OMISSIONS OF FACT CONSTITUTE
FEDERAL CRIMINAL VIOLATIONS (SEE 18 U.S.C. 1001)
